A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

Platysma Prominence Clinical Trial

Official title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence

Status Completed

Clinical Trial Summary

The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence. Study doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 400 participants will be enrolled in the study in the United States and Canada. Participants will receive either intramuscular injections of onabotulinumtoxinA (BOTOX) or placebo. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at the study site.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Platysma Prominence

• NCT number: NCT04949399
• Study type: Interventional
• Source: Allergan
• Status: Completed
• Phase: Phase 3
• Start date: July 8, 2021
• Completion date: December 20, 2022